Glucoză Stada Hemofarm

Glucoză Stada Hemofarm is an intravenous preparation that contains glucose, anhydrous as its sole active ingredient. The product is supplied in a sterile solution intended for parenteral administration, providing a rapid source of carbohydrate for patients who require immediate glucose supplementation. It is marketed in the European Union and follows the regulatory standards applicable to injectable medicines. These formulations are typically used in hospital settings under medical supervision.

Glucoză Stada Hemofarm is used when rapid intravenous glucose is required to support metabolic needs.

- Treatment of hypoglycemia in patients unable to take oral glucose. - Provision of energy substrate during surgery or anesthesia. - Support for patients receiving parenteral nutrition who need carbohydrate supplementation. - Management of electrolyte imbalances where glucose infusion assists in intracellular fluid shifts. - Temporary glucose replacement in critical care settings such as trauma or sepsis. - Adjunctive therapy in diagnostic procedures that require controlled blood glucose levels.

Intravenous administration of glucose, anhydrous can be associated with a range of observed effects, most of which are related to the rapid increase in blood sugar levels. These effects are generally dose‑dependent and may vary with the patient’s underlying health status.

Common: - Transient hyperglycemia with elevated blood glucose measurements. - Mild nausea or vomiting during or after infusion. - Local irritation or pain at the injection site. - Fluid overload signs such as mild peripheral edema. - Headache or dizziness during infusion.

Serious: - Severe hyperglycemia leading to osmotic diuresis or ketoacidosis in susceptible individuals. - Allergic reactions ranging from urticaria to anaphylaxis. - Electrolyte disturbances, particularly hyponatremia, due to rapid fluid shifts. - Cardiac arrhythmias associated with rapid glucose shifts. - Severe hyperglycemia leading to osmotic diuresis or ketoacidosis in susceptible individuals.

When using Glucoză Stada Hemofarm, clinicians should observe several precautions to minimize risks and ensure safe administration.

- Verify patient’s blood glucose level before infusion to avoid excessive hyperglycemia. - Adjust infusion rate in patients with renal or cardiac insufficiency to prevent fluid overload. - Use aseptic technique and inspect the solution for particulate matter or discoloration before administration. - Monitor electrolytes, especially sodium and potassium, during and after infusion. - Consider contraindications in patients with known hypersensitivity to glucose solutions. - Document infusion details, including volume and rate, in the patient’s medical record. - Ensure compatible IV lines and avoid mixing with incompatible medications.

Glucose solutions can interact with certain medications or clinical conditions, requiring careful assessment before co‑administration.

Avoid: - Co‑administration with hypertonic dextrose solutions, which may cause severe hyperglycemia. - Simultaneous infusion of insulin without appropriate dose adjustment, risking rapid glucose fluctuations. - Use with medications that contain potassium chloride in high concentrations, increasing risk of hyperkalemia.

Use with caution: - Concurrent administration of diuretics, which may alter fluid and electrolyte balance. - Patients receiving beta‑blockers, as they can mask hypoglycemia symptoms. - Situations involving corticosteroid therapy, which can exacerbate glucose intolerance.